Alliance for Clinical Trials in Oncology is recruiting patients for a PHASE2 clinical trial testing nivolumab plus ipilimumab for mesothelioma.
The trial, designated NCT05647265, aims to enroll up to 26 participants at 126 sites, including locations in Alaska, Arizona, California.
About the Study
This phase II trial evaluates the safety and effectiveness of giving immunotherapy (nivolumab and ipilimumab) before surgery for controlling disease in patients with stage I-IIIa sarcomatoid mesothelioma. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving immunotherapy before surgery may be more effective at controlling disease in patients with sarcomatoid mesothelioma than giving immunotherapy alone.
Treatment Approach
This trial uses a combination of checkpoint inhibitors that was FDA-approved for mesothelioma in 2020.
Key trial details:
- Phase: PHASE2
- Sponsor: Alliance for Clinical Trials in Oncology
- Enrollment target: 26
- Status: RECRUITING
Why This Trial Matters
Study Locations
The trial is recruiting at:
- Anchorage Associates in Radiation Medicine, Alaska
- Anchorage Radiation Therapy Center, Alaska
- Alaska Breast Care and Surgery LLC, Alaska
- Alaska Oncology and Hematology LLC, Alaska
- Alaska Women’s Cancer Care, Alaska
How to Enroll
Patients interested in this trial should:
- Discuss eligibility with their oncologist
- Review the full eligibility criteria on ClinicalTrials.gov
- Contact the study coordinator for screening